Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2021

Open Access 01-03-2021 | Sarcopenia | short review

Sarcopenia in cancer—a focus on elderly cancer patients

Authors: Dr. Maximilian Marhold, PhD, Thais Topakian, MSc, Dr. Matthias Unseld, PhD

Published in: memo - Magazine of European Medical Oncology | Issue 1/2021

Login to get access

Summary

Geriatric assessments, nutritional counseling and monitoring of muscle health before and during therapy are of high clinical significance in the management of elderly cancer patients. Criteria, data and cut-offs characterizing cancer-related geriatric sarcopenia are sparse and no consensus about definitions exists to date. We hence highlight a need for clinical trials focusing on sarcopenia in elderly cancer patients, based on its high prevalence and potential negative consequences on therapy outcomes, mortality, quality of life and physical mobility.
Literature
1.
Colloca G, et al. Muscoloskeletal aging, sarcopenia and cancer. J Geriatr Oncol. 2019;10(3):504–9.CrossRef
2.
von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010;1(2):129–33.CrossRef
3.
Vega MC, Laviano A, Pimentel GD. Sarcopenia and chemotherapy-mediated toxicity. Einstein. 2016;14(4):580–4.CrossRef
4.
McDevitt TM, et al. Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans. Cancer Res. 1995;55(7):1458–63.PubMed
5.
Todorov PT, Field WN, Tisdale MJ. Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br J Cancer. 1999;80(11):1734–7.CrossRef
6.
Prado CM, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–35.CrossRef
7.
Landi F, et al. Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clin Nutr. 2012;31(5):652–8.CrossRef
8.
Pamoukdjian F, et al. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review. Clin Nutr. 2018;37(4):1101–13.CrossRef
9.
Wang B, et al. Cancer-related fatigue and biochemical parameters among cancer patients with different stages of sarcopenia. Support Care Cancer. 2020;28(2):581–8.CrossRef
10.
Zhang XM, et al. Sarcopenia as a predictor of mortality in women with breast cancer: a meta-analysis and systematic review. BMC Cancer. 2020;20(1):172.CrossRef
11.
Kumar A, et al. Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecol Oncol. 2016;142(2):311–6.CrossRef
12.
Dohzono S, et al. Low paravertebral muscle mass in patients with bone metastases from lung cancer is associated with poor prognosis. Support Care Cancer. 2020;28(1):389–94.CrossRef
13.
Nakamura N, et al. Prognostic impact of skeletal muscle assessed by computed tomography in patients with acute myeloid leukemia. Ann Hematol. 2019;98(2):351–9.CrossRef
14.
Chargi N, et al. Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer. Eur Arch Otorhinolaryngol. 2019;276(5):1475–86.CrossRef
15.
Lee JS, et al. Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer. Plos One. 2018;13(8):e202700.CrossRef
16.
Vashi PG, et al. Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer. Plos One. 2019;14(6):e218761.CrossRef
17.
Takahashi K, et al. Prognostic significance of skeletal muscle loss during early postoperative period in elderly patients with esophageal cancer. Ann Surg Oncol. 2019;26(11):3727–35.CrossRef
18.
Shiroyama T, et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD‑1 inhibitors: a preliminary retrospective study. Sci Rep. 2019;9(1):2447.CrossRef
19.
Narsale A, et al. Cancer-driven changes link T cell frequency to muscle strength in people with cancer: a pilot study. J Cachexia Sarcopenia Muscle. 2019;10(4):827–43.CrossRef
20.
Tsukioka T, et al. Positive correlation between sarcopenia and elevation of neutrophil/lymphocyte ratio in pathological stage IIIA (N2-positive) non-small cell lung cancer patients. Gen Thorac Cardiovasc Surg. 2018;66(12):716–22.CrossRef
21.
Nipp RD, et al. Sarcopenia is associated with quality of life and depression in patients with advanced cancer. Oncologist. 2018;23(1):97–104.CrossRef
22.
Galvao DA, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008;102(1):44–7.CrossRef
23.
Minetto MA, et al. Diagnostic work-up in steroid myopathy. Endocrine. 2018;60(2):219–23.CrossRef
24.
Davis MP, Panikkar R. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Ann Palliat Med. 2019;8(1):86–101.CrossRef
25.
Sugiyama K, et al. Baseline sarcopenia and skeletal muscle loss during chemotherapy affect survival outcomes in metastatic gastric cancer. Anticancer Res. 2018;38(10):5859–66.CrossRef
26.
Botsen D, et al. Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients. BMC Cancer. 2018;18(1):955.CrossRef
27.
Prado CM, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920–6.CrossRef
28.
Kurita Y, et al. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology. 2019;19(1):127–35.CrossRef
29.
Panje CM, et al. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: a SAKK 75/08 substudy. Radiat Oncol. 2019;14(1):166.CrossRef
30.
Kurk SA, et al. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2018;9(5):909–19.CrossRef
31.
Aleixo GFP, et al. Bioelectrical impedance analysis for the assessment of sarcopenia in patients with cancer: a systematic review. Oncologist. 2020;25(2):170–82.CrossRef
32.
33.
Adams SC, et al. Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. Breast Cancer Res Treat. 2016;158(3):497–507.CrossRef
34.
35.
Bozzetti F. Nutritional interventions in elderly gastrointestinal cancer patients: the evidence from randomized controlled trials. Support Care Cancer. 2019;27(3):721–7.CrossRef
36.
Fukushima H, Fujii Y, Koga F. Metabolic and molecular basis of sarcopenia: implications in the management of urothelial carcinoma. Int J Mol Sci. 2019;20(3):760.CrossRef
Metadata
Title
Sarcopenia in cancer—a focus on elderly cancer patients
Authors
Dr. Maximilian Marhold, PhD
Thais Topakian, MSc
Dr. Matthias Unseld, PhD
Publication date
01-03-2021
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2021
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00637-6

Other articles of this Issue 1/2021

memo - Magazine of European Medical Oncology 1/2021 Go to the issue

short review

ASCO 2020 non-small lung cancer (NSCLC) personal highlights

review

Geriatric oncology: questions, answers and guidelines

short review

Diagnosis and supportive therapeutic management of cardiac light chain amyloidosis—a cardiologist’s perspective

short review

Cancer prehabilitation—a short review

short review

Monoclonal gammopathy of undetermined significance (MGUS): where is the hidden danger? Definition and work-up

short review

Pain and palliative care treatment in daily practice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits